---
document_datetime: 2023-09-21 21:56:59
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fycompa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: fycompa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.023573
conversion_datetime: 2025-12-28 03:14:34.947165
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fycompa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0068/G            | This was an application for a group of variations. | 02/05/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |            |             |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9255/ 202207 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/02/2023 | 27/04/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202207. |
| IA/0067            | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                 | 16/01/2023 | n/a        |             |                                                                                                                                           |
| IAIN/0066          | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                            | 22/11/2022 | n/a        |             |                                                                                                                                           |
| IAIN/0065          | B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product                                                                                                                                                                                                                                                                       | 22/11/2022 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0063            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                            | 24/08/2022   | 27/04/2023   | SmPC, Labelling and PL   |                                                                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9255/ 202107 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                  | 24/02/2022   | 25/04/2022   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202107.          |
| N/0062             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                          | 11/03/2022   | 27/04/2023   | PL                       |                                                                                                                                                    |
| N/0060             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                          | 10/09/2021   | 25/04/2022   | PL                       |                                                                                                                                                    |
| IB/0058/G          | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.z - Stability of FP - Other variation | 17/06/2021   | 25/04/2022   | SmPC                     | To update section 6.3 of the Summary of Product Characteristics for Fycompa 0.5 mg/ml oral suspension (EU/1/12/776/024) from 2 years to 30 months. |
| IA/0059            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                       | 03/06/2021   | n/a          |                          |                                                                                                                                                    |
| PSUSA/9255/ 202007 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                  | 25/02/2021   | 21/04/2021   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202007.          |
| IA/0057            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                             | 10/03/2021   | 25/04/2022   | Annex II and             |                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            | PL                  |                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|--------------------------------------------------------------------|
| IA/0056   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/01/2021 | n/a        |                     |                                                                    |
| II/0047   | Extension of Indication to include the paediatric patients from 4 to 11 years of age for the adjunctive treatment of partial-onset seizures with or without secondary generalisation and from 7 to 11 years of age for the adjunctive treatment of primary generalised tonic-clonic seizures with idiopathic generalised epilepsy for Fycompa. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 4.5 has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 17/09/2020 | 10/11/2020 | SmPC and PL         | Please refer to Scientific Discussion 'Fycompa-H-C-002434- II-0047 |
| N/0052    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/07/2020 | 10/11/2020 | PL                  |                                                                    |
| IG/1263   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                       | 24/06/2020 | 10/11/2020 | Annex II and PL     |                                                                    |
| IG/1260/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/06/2020 | 10/11/2020 | SmPC, Labelling and |                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            | PL          |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9255/ 201907 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                                                                                                                           | 27/02/2020 | 28/04/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/201907. |
| IA/0051            | B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                              | 25/10/2019 | n/a        |             |                                                                                                                                           |
| IA/0049            | B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                         | 20/10/2019 | n/a        |             |                                                                                                                                           |
| IA/0048            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                       | 15/10/2019 | n/a        |             |                                                                                                                                           |
| IB/0046/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                 | 25/06/2019 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0045/G        | This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging -                                                                                                                  | 27/03/2019 | n/a |                                   |
| PSUSA/9255/ 201807 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                                                                                                                                                                                                        | 14/02/2019 | n/a | PRAC Recommendation - maintenance |
| IG/1044/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release                                                                                                                                                                                                                                                          | 22/01/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                    | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                  |            |            |                        |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1008            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 30/11/2018 | 29/10/2019 | Annex II and PL        |                                                                                                                                           |
| T/0040             | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 23/08/2018 | 21/09/2018 | SmPC, Labelling and PL |                                                                                                                                           |
| IAIN/0039          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/07/2018 | n/a        |                        |                                                                                                                                           |
| PSUSA/9255/ 201707 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                               | 22/02/2018 | 23/04/2018 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/201707. |
| N/0038             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                       | 22/11/2017 | 30/01/2018 | PL                     |                                                                                                                                           |
| PSUSA/9255/ 201701 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                               | 01/09/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                         |
| R/0035             | Renewal of the marketing authorisation.                                                                                                                                                                                                | 26/01/2017 | 06/04/2017 |                        | Based on the review of data on quality, safety and efficacy,                                                                              |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                        |            |            |      | the CHMP considered that the benefit-risk balance of Fycompa in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034/G          | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/02/2017 | 30/01/2018 | SmPC | In a retrospective study of clinical practice, 51 patients with epilepsy who received perampanel as adjunctive treatment converted to perampanel monotherapy. The majority of these patients had a history of partial onset seizures. Of these, 14 patients (27%) reverted to adjunctive therapy in the following months. Thirty four (34) patients were followed up for at least 6 months and, of these, 24 patients (71%) remained on perampanel monotherapy for at least 6 months. Ten (10) patients were followed up for at least 18 months and, of these, 3 patients (30%) remained on perampanel monotherapy for at least 18 months. Withdrawal of a concomitant CYP450 3A enzyme inducer can be expected to increase plasma concentrations of |
| PSUSA/9255/ 201607 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                               | 09/02/2017 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0030            | Update of sections 5.1 and 5.2 of the SmPC to reflect the results from study E2007-G000-235. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                         | 20/10/2016 | 06/04/2017 | SmPC | A 19-week, randomised, double-blind, placebo-controlled study with an open-label extension phase (Study 235) was performed to assess the short-term effects on cognition of Fycompa (target dose range of 8 to 12 mg once daily) as adjunctive therapy in 133 (Fycompa n=85, placebo n=48) adolescent patients, ages 12 to less than 18 years old, with inadequately controlled partial-onset seizures. Cognitive function was assessed by the Cognitive Drug Research (CDR) System Global Cognition t-Score, which is a                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                    |                                                               |            |            |                        | composite score derived from 5 domains testing Power of Attention, Continuity of Attention, Quality of Episodic Secondary Memory, Quality of Working Memory, and Speed of Memory. The mean change (SD) from baseline to end of double-blind treatment (19 weeks) in CDR System Global Cognition t-Score was 1.1 (7.14) in the placebo group and (minus) -1.0 (8.86) in the perampanel group, with the difference between the treatment groups in LS means (95% CI) = (minus) 2.2 (5.2, 0.8). There was no statistically significant difference between the treatment groups (p = 0.145). CDR System Global Cognition t-Scores for placebo and perampanel were 41.2 (10.7) and 40.8 (13.0), respectively at the baseline. For patients with perampanel in the open label extension (n = 112), the mean change (SD) from baseline to end of open-label treatment (52 weeks) in CDR System Global Cognition t- Score was (minus) 1.0 (9.91). This was not statistically significant (p = 0.96). After up to 52 weeks of treatment with perampanel (n = 114), no effect on bone growth was observed. No effects on weight, height and sexual development were seen following up to 104 weeks of treatment (n = 114).   |
|--------------------|---------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0025             | Annex I_2.(d) Change or addition of a new pharmaceutical form | 21/07/2016 | 19/09/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/9255/ 201601 | Periodic Safety Update EU Single assessment - perampanel      | 02/09/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0031/G          | This was an application for a group of variations.            | 04/05/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0028            | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                            | 24/02/2016 | 19/09/2016 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/9255/ 201507 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                                                                                                                                                                                  | 11/02/2016 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0023            | Update of sections 4.5 and 5.2 in order to update the safety information based on the results of a mass balance study. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                  | 19/11/2015 | 19/09/2016 | SmPC | A human mass balance study which achieved good recovery of radioactivity and where samples were assessed for metabolite concentration throughout the time course of sample collection was completed Post Authorisation Measure (PAM) to address a key remaining gap 'bridging' in vitro data and in vivo data with regards to the potential role of CYP1A2 in the metabolism of perampanel. The MAH submitted a procedure to update of sections 4.5 and 5.2 in order to update the safety information based on the results of a mass balance study. |
| II/0024/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                        | 17/09/2015 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                        |            |            |             |                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------|
| PSUSA/9255/ 201501 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/09/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                  |
| IA/0026            | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/07/2015 | n/a        |             |                                                                                                    |
| II/0016            | Extension of indication to include a new indication for Fycompa for adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Consequently, the MAH proposed an update of sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC. In addition, minor editorial changes and amendments to improve the clarity and readability of the information was implemented throughout the product information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 21/05/2015 | 22/06/2015 | SmPC and PL | Please refer to the scientific discussion Fycompa EMEA/H/C/002434/II/0016 for further information. |

<div style=\"page-break-after: always\"></div>

| IAIN/0022          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                 | 26/05/2015   | n/a        |      |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------|
| IB/0021/G          | This was an application for a group of variations. B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 13/05/2015   | 22/06/2015 | SmPC |                                   |
| PSUSA/9255/ 201407 | Periodic Safety Update EU Single assessment - perampanel                                                                                                                                                                                           | 12/02/2015   | n/a        |      | PRAC Recommendation - maintenance |
| IA/0019            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                               | 12/01/2015   | n/a        |      |                                   |
| IB/0017            | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                             | 17/09/2014   | n/a        |      |                                   |
| IB/0015/G          | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other           | 15/09/2014   | 22/06/2015 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                   |            |            |                       |                                                                                                                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0014 | Periodic Safety Update                                                                                                                                                                                      | 11/09/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                 |
| PSUV/0010 | Periodic Safety Update                                                                                                                                                                                      | 06/02/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                 |
| IB/0013   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                  | 20/12/2013 | n/a        |                       |                                                                                                                                   |
| IA/0012   | B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients | 12/12/2013 | n/a        |                       |                                                                                                                                   |
| IAIN/0011 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                          | 25/11/2013 | n/a        |                       |                                                                                                                                   |
| PSUV/0009 | Periodic Safety Update                                                                                                                                                                                      | 19/09/2013 | 13/11/2013 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0009. |
| IG/0345   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                             | 03/09/2013 | n/a        |                       |                                                                                                                                   |
| IA/0007   | B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to            | 29/07/2013 | n/a        |                       |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | excipients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |                                                                                                                                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0006 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/05/2013 | n/a        |                        |                                                                                                                                                                                   |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/01/2013 | n/a        |                        | The Marketing Authorisation Holder (MAH) took the opportunity to undertake user testing for the three language package leaflet. It was confirmed that the text remains unchanged. |
| IB/0004   | B.II.f.1.b.z - Stability of FP - Extension of the shelf life of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/11/2012 | 13/11/2013 | SmPC                   |                                                                                                                                                                                   |
| IB/0003/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished | 27/09/2012 | 29/10/2012 | SmPC, Labelling and PL |                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                       |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0002   | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 05/09/2012 | n/a |
| IB/0001/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.5.b - Change to in-process tests or limits | 04/09/2012 | n/a |

<div style=\"page-break-after: always\"></div>

| applied during the manufacture of the finished   |
|--------------------------------------------------|
| product - Addition of a new tests and limits     |